<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409981</url>
  </required_header>
  <id_info>
    <org_study_id>BMT - Pac 2</org_study_id>
    <nct_id>NCT00409981</nct_id>
  </id_info>
  <brief_title>Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR II)</brief_title>
  <official_title>Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <brief_summary>
    <textblock>
      The PACCOCATH ISR II study is a randomized, double-blinded German multicenter trial on the
      efficacy and tolerance of a paclitaxel coated balloon catheter in coronary in-stent
      restenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Drug-eluting stents have shown promising anti-restenotic effects in clinical
      trials. It may be preferable, however, to avoid the stent-in-stent approach in treating
      in-stent restenosis (ISR). In prior animal trials, we demonstrated a highly significant
      reduction of neointimal formation by drug-eluting balloon catheters (DEB). The aim of the
      PACCOCATH ISR study is to investigate the novel DEB in the treatment of ISR.

      Methods and results: The PACCOCATH ISR study is a randomized, double-blind German multicenter
      trial on the efficacy and tolerance of the DEB in coronary ISR. Patients are randomized to
      rePTCA of ISR either using the coated PTCA balloon (3 µg paclitaxel/mm² balloon surface) or a
      non-coated balloon of the same type (n=56 patients). Balloon inflation time is 60 seconds in
      both cases. Major inclusion criteria are an ISR in a coronary artery with a diameter stenosis
      of at least 70%, &lt; 30 mm length, and a vessel diameter of 2.5 to 3.5 mm. The primary endpoint
      is late lumen loss after 6 months (independent angiographic core lab). Secondary endpoints
      are binary restenosis rate and major adverse cardiac events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date>June 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>angiographic late lumen loss</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>binary restenosis rate; major adverse cardiac events</measure>
  </secondary_outcome>
  <enrollment>56</enrollment>
  <condition>Coronary Restenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>paclitaxel coated balloon catheter (device with drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Clinical evidence of stable or unstable angina or a positive functional study

          -  Single, restenotic lesion in a stented coronary artery (allowed are multiple lesions
             but only the target lesion is amenable for percutaneous intervention, i.e. no ‘staged’
             procedures involving non-target lesions)

          -  Diameter stenosis &gt; 70% (visual estimate)

          -  Stented segment length &lt; 30 mm

          -  Vessel diameter =&gt; 2.5 mm

          -  Female patients can enter this study if they are post-menopausal for at least two
             years or have undergone hysterectomy or sterilization

          -  Signed patient informed consent form

          -  Patients and treating physicians agree that the patient will return for all required
             post procedure follow-up assessments as defined in the clinical protocol

        Exclusion Criteria:

          -  Left ventricular ejection fraction of &lt; 30%

          -  Target lesion/vessel with any of the following characteristics: Clear angiographic
             calcification in the target lesion or greater than mild calcification in the proximal
             vessel (minimally radiopaque densities that are discrete and non-linear). Visible
             thrombus proximal to the lesion.

          -  Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel,
             abciximab, paclitaxel, or a sensitivity to contrast media which cannot be adequately
             pre-medicated.

          -  Other medical illness (i.e. cancer, liver disease or congestive heart failure) that
             may require cytostatic or radiation therapy causing the subject to be non-compliant
             with the protocol, confound the data interpretation or is associated with limited
             life-expectancy (i.e., less than two years).

          -  Severe chronic renal insufficiency.

          -  Significant gastrointestinal (GI) bleed within the past six months. History of
             bleeding diathesis or coagulopathy or will refuse blood transfusions.

          -  Extensive peripheral vascular disease that precludes safe 6 French sheath insertion
             and/or requires additional anti-platelet and/or anti-coagulation treatment.

          -  Participating in another device or drug study within the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Scheller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saarland, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg / Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologie, Campus Mitte, Charite</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologie, Campus Virchow-Klinikum, Charite</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik III, Abt. Kardiologie und Angiologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. Medizinische Klinik, Universitaetsklinikum</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004 Aug 17;110(7):810-4. Epub 2004 Aug 9.</citation>
    <PMID>15302790</PMID>
  </reference>
  <reference>
    <citation>Speck U, Scheller B, Abramjuk C, Grossmann S, Mahnkopf D, Simon O. Inhibition of restenosis in stented porcine coronary arteries: uptake of Paclitaxel from angiographic contrast media. Invest Radiol. 2004 Mar;39(3):182-6.</citation>
    <PMID>15076010</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Speck U, Schmitt A, Böhm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003 Oct 15;42(8):1415-20.</citation>
    <PMID>14563585</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Böhm M, Stoll HP. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J. 2003 Aug;24(15):1462-7.</citation>
    <PMID>12909076</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006 Nov 16;355(20):2113-24. Epub 2006 Nov 13.</citation>
    <PMID>17101615</PMID>
  </reference>
  <reference>
    <citation>Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Boehm M, Hamm B. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology. 2006 Aug;240(2):411-8.</citation>
    <PMID>16864669</PMID>
  </reference>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2006</study_first_posted>
  <last_update_submitted>December 11, 2006</last_update_submitted>
  <last_update_submitted_qc>December 11, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2006</last_update_posted>
  <keyword>in stent restenosis</keyword>
  <keyword>paclitaxel coated balloon catheter</keyword>
  <keyword>paccocath</keyword>
  <keyword>drug eluting balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

